Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Studies:…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…

ASH 2021 Conference Coverage on VuMedi

K. Kim

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …

ASH 2021 Conference Coverage on VuMedi

E. Oliva

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

ASH 2021 Conference Coverage on VuMedi

J. Bewersdorf

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

ASH 2021 Updates on the Management of Polycythemia Vera

ASH 2021 Conference Coverage on VuMedi

A. Kuykendall

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…

ASH 2021 Conference Coverage on VuMedi

A. Jain

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…

ASH 2021 Conference Coverage on VuMedi

M. Shah

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

ASH 2021 Highlights in MPN

ASH 2021 Conference Coverage on VuMedi

P. Bose

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

ASH 2021 Conference Coverage on VuMedi

M. Kremyanskaya

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …

ASH 2021 Conference Coverage on VuMedi

P. Bose

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

ASH 2021 Conference Coverage on VuMedi

F. Passamonti

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…

ASH 2021 Conference Coverage on VuMedi

J. Garcia

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…

ASH 2021 Conference Coverage on VuMedi

A. Brunner

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…

ASH 2021 Conference Coverage on VuMedi

H. Gill

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

Richard T. Silver

A Real-World Evaluation of the Association Between Elevated Blood Co…

Aaron Gerds

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…

ASH 2021 Conference Coverage on VuMedi

A. Tefferi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas